Literature DB >> 33750947

Development of human hepatocellular carcinoma in X-linked severe combined immunodeficient pigs: An orthotopic xenograft model.

Kohei Mishima1, Osamu Itano1,2, Sachiko Matsuda1, Shunichi Suzuki3, Akira Onishi3,4, Masashi Tamura5, Masanori Inoue5, Yuta Abe1, Hiroshi Yagi1, Taizo Hibi6, Minoru Kitago1, Masahiro Shinoda1, Yuko Kitagawa1.   

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common primary tumor and the third leading cause of cancer-related deaths worldwide. Rodent models of HCC have contributed to the advancement of studies investigating liver carcinogenesis, tumor-host interactions, and drug screening. However, their small size renders them unsuitable for surgical or clinical imaging studies, necessitating the development of larger-size HCC models. Here, we developed a xenograft model of human HCC in X-linked interleukin-2 receptor gamma chain gene (Il2rg)-targeted severe combined immunodeficient (SCID) pigs. HepG2 cell suspension in serum-free medium containing 50% membrane matrix was directly injected into the liver parenchyma of eight X-linked Il2rg-targeted SCID pigs (6.6-15.6 kg) via ultrasonography-guided percutaneous puncture. Tumor engraftment was evaluated weekly using ultrasonography, and cone-beam computed tomography was performed during arterial portography (CTAP) and hepatic arteriography (CTHA) to evaluate the hemodynamics of engrafted tumors. The engrafted tumors were histologically analyzed following necropsy and assessed for pathological similarities to human HCCs. Macroscopic tumor formation was observed in seven of the eight pigs (simple nodular tumors in three and multinodular tumors in four). Engrafted tumors were identified as low-echoic upon ultrasonography and as perfusion-defect nodules on the CTAP images. Meanwhile, CTHA showed that the tumors were hyperattenuating. Further, histopathological findings of the engrafted tumors were consistent with those of human HCC. In conclusion, the porcine model of human HCC, successfully generated herein, might help develop more effective therapeutic strategies for HCC.

Entities:  

Year:  2021        PMID: 33750947      PMCID: PMC7984615          DOI: 10.1371/journal.pone.0248352

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  16 in total

1.  First In Vivo Test of Thermoembolization: Turning Tissue Against Itself Using Transcatheter Chemistry in a Porcine Model.

Authors:  Erik N K Cressman; Chunxiao Guo
Journal:  Cardiovasc Intervent Radiol       Date:  2018-06-05       Impact factor: 2.740

2.  Improved, Shorter-Latency Carcinogen-Induced Hepatocellular Carcinoma Model in Pigs.

Authors:  Jason Ho; Matthew Ware; Justin Law; Aaditya Nagaraj; Shilpa Jain; Jesse Rios; Reynaldo Calderon; Barry Toombs; Andrew Anderson; Collin Bray; Steven Curley; Stuart James Corr
Journal:  Oncology       Date:  2018-09-28       Impact factor: 2.935

3.  N-nitrosodiethylamine-induced pig liver hepatocellular carcinoma model: radiological and histopathological studies.

Authors:  Xiao Li; Xiangping Zhou; Yongsong Guan; Yi-Xiang J Wang; Diane Scutt; Qi-Yong Gong
Journal:  Cardiovasc Intervent Radiol       Date:  2006 May-Jun       Impact factor: 2.740

4.  Creation of porcine liver tumor using human hepatoma cell lines: experimental study.

Authors:  R Rai; P Flecknell; C Richardson; D M Manas
Journal:  Cancer Biol Ther       Date:  2005-06-05       Impact factor: 4.742

5.  Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs.

Authors:  Jennifer Mitchell; Peggy T Tinkey; Rony Avritscher; Carolyn Van Pelt; Ghazaleh Eskandari; Suraj Konnath George; Lianchun Xiao; Erik Cressman; Jeffrey S Morris; Asif Rashid; Ahmed O Kaseb; Hesham M Amin; Rajesh Uthamanthil
Journal:  Oncology       Date:  2016-06-16       Impact factor: 2.935

6.  Blockade of endothelial G(i) protein enhances early engraftment in intraportal cell transplant to mouse liver.

Authors:  Javier Alfaro; Montserrat Grau; Manuel Serrano; Ana I Checa; Luis Miguel Criado; Enrique Moreno; Estela Paz-Artal; Mario Mellado; Antonio Serrano
Journal:  Cell Transplant       Date:  2012       Impact factor: 4.064

Review 7.  Matrigel: from discovery and ECM mimicry to assays and models for cancer research.

Authors:  Gabriel Benton; Irina Arnaoutova; Jay George; Hynda K Kleinman; Jennifer Koblinski
Journal:  Adv Drug Deliv Rev       Date:  2014-07-02       Impact factor: 15.470

Review 8.  Experimental mouse models for hepatocellular carcinoma research.

Authors:  Femke Heindryckx; Isabelle Colle; Hans Van Vlierberghe
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

9.  Il2rg gene-targeted severe combined immunodeficiency pigs.

Authors:  Shunichi Suzuki; Masaki Iwamoto; Yoriko Saito; Daiichiro Fuchimoto; Shoichiro Sembon; Misae Suzuki; Satoshi Mikawa; Michiko Hashimoto; Yuki Aoki; Yuho Najima; Shinsuke Takagi; Nahoko Suzuki; Emi Suzuki; Masanori Kubo; Jun Mimuro; Yuji Kashiwakura; Seiji Madoiwa; Yoichi Sakata; Anthony C F Perry; Fumihiko Ishikawa; Akira Onishi
Journal:  Cell Stem Cell       Date:  2012-06-14       Impact factor: 24.633

10.  Development of Severe Combined Immunodeficient (SCID) Pig Models for Translational Cancer Modeling: Future Insights on How Humanized SCID Pigs Can Improve Preclinical Cancer Research.

Authors:  Adeline N Boettcher; Crystal L Loving; Joan E Cunnick; Christopher K Tuggle
Journal:  Front Oncol       Date:  2018-11-30       Impact factor: 6.244

View more
  2 in total

Review 1.  Swine models for translational oncological research: an evolving landscape and regulatory considerations.

Authors:  Adeline N Boettcher; Kyle M Schachtschneider; Lawrence B Schook; Christopher K Tuggle
Journal:  Mamm Genome       Date:  2021-09-02       Impact factor: 3.224

2.  Three-dimensional assessment of vascular cooling effects on hepatic microwave ablation in a standardized ex vivo model.

Authors:  C A Neizert; H N C Do; M Zibell; C Rieder; D Sinden; S M Niehues; J L Vahldiek; K S Lehmann; F G M Poch
Journal:  Sci Rep       Date:  2022-10-12       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.